Revian Red Hair Growth System Takes on CCCA in Second Study
Based on the promising results of a previous study conducted by Dr. Amy McMichael, Chair and Professor of Dermatology at Wake Forest University School of Medicine, this larger study will enroll participants between the ages of eighteen and sixty-five with a biopsy or trichoscopy proven diagnosis of CCCA Stage II-IV.
Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA).
The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wireless cap controlled by a mobile app that uses patented dual wavelength LED technology to treat hair loss.
Based on the promising results of a previous study conducted by Dr. Amy McMichael, Chair and Professor of Dermatology at Wake Forest University School of Medicine, this larger study will enroll participants between the ages of eighteen and sixty-five with a biopsy or trichoscopy proven diagnosis of CCCA Stage II-IV.
The purpose of this study is to determine if the Revian Red system could be an effective treatment for CCCA by recruiting hair follicles back to anagen growth or through its demonstrated ability to decrease inflammation.
"While we do not know the exact cause of CCCA, we do know that inflammation is a major factor in how this form of alopecia develops. We hope to demonstrate the Revian Red system can improve scalp symptoms, reduce hair loss, and promote maturation of vellus and intermediate hairs in non-scarred areas of the scalp in those affected by CCCA" says Dr. McMichael in a news release.
Subjects will use the Revian Red system once daily for 10 minutes for a total of 6 months. Investigators anticipate that the data and measurements from this study will contribute to the design of a larger, randomized clinical trial in the future.
"It would be of great benefit to determine if there is any advantage in using the Revian Red system along with other anti-inflammatory therapies to relieve symptoms or promote hair regrowth in follicles that have not yet become scarred," adds Co-Investigator, Dr. Ivie Obeime, research fellow in the Department of Dermatology at Wake Forest School of Medicine.
"Management of CCCA is difficult due to the lack of current treatments causing physicians to resort to the use of oral antibiotics and anti-inflammatory therapies such as intralesional and topical steroids. We believe those suffering from this debilitating disease will not have to endure painful scalp injections and the negative side-effects of steroids and antibiotics once the Revian Red system is proven successful as a non-invasive and drug-free therapy in the treatment of CCCA" says John Oakley, CEO of REVIAN.